{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:55Z","timestamp":1791908215969,"version":"4.3.4"},"reference-count":38,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Aim: To determine the efficacy and safety of vericiguat in a real-world cohort of patients with heart failure (HF) with reduced ejection fraction in Spain. Methods: A prospective observational study of HF with reduced ejection fraction patients with a recent episode of worsening HF, requiring IV therapy, and who initiated vericiguat in a HF outpatient clinic was carried out. Of the 103 patients included, 28 (27.2%) were women. Results: At baseline, the mean age was 71.3 \u00b1 9.4 years, the median ejection fraction was 34% (interquartile range; IQR 28\u201339%) and N-terminal pro-B-type natriuretic peptide was 2,034 pg\/ml (IQR 910\u20133,372 pg\/ml). Regarding HF treatments, 99% of patients were taking \u03b2-blockers, 97.1% sodium-glucose cotransporter 2 inhibitors, 96.1% sacubitril\u2013valsartan, 91.2% mineralocorticoid receptor antagonists and 93.2% loop diuretics. After 1 year of treatment with vericiguat, New York Heart Association functional class improved from 36.9 and 63.1% in classes II and III to 72.1 and 16.3%, respectively, as did the visual analogue scale score, from 60 (50\u201375) to 70 (50\u201385; both p&lt;0.001). N-terminal pro-B-type natriuretic peptide levels decreased from 2,034 pg\/ml (IQR 910\u20133,372 pg\/ml) to 1,282 pg\/ml (IQR 562\u20133,303 pg\/ml; p=0.034). The dosage of angiotensin receptor\u2013neprilysin inhibitors increased significantly (p&lt;0.001), and the dose of furosemide was reduced (p=0.032). The number of HF-related hospitalisations\/emergency department visits within the previous year was 1.9 \u00b1 1.3, decreasing to 0.55 \u00b1 0.98 (p&lt;0.001). At study end, 7.8% of patients had died (one-quarter of HF). Only 11.7% of patients discontinued vericiguat (6.8% owing to hypotension), and 77.7% achieved the target dose of 10 mg. Conclusion: In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life, reductions in natriuretic peptide levels and clinical events, and a good safety profile.<\/jats:p>","DOI":"10.15420\/cfr.2025.45","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:46:16Z","timestamp":1776444376000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Vericiguat in a Real-life Population with Heart Failure after 1 Year of Treatment: The VERITA Study"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-5850","authenticated-orcid":false,"given":"Mario","family":"Galv\u00e1n-Ruiz","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6116-2579","authenticated-orcid":false,"given":"Miguel Fern\u00e1ndez","family":"de Sanmamed-Gir\u00f3n","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2631-6230","authenticated-orcid":false,"given":"Mar\u00eda","family":"del Val Groba-Marco","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Rojo-Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pe\u00f1a-Saavedra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Mart\u00edn-Bou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Andrade-Guerra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Antonio","family":"Suarez-Benitez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Aguiar-Bujanda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Burgos-Ram\u00edrez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Caballero-Dorta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2475-2616","authenticated-orcid":false,"given":"Antonio","family":"Garc\u00eda-Quintana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s4vhs88","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref0","unstructured":"Martin SS, Aday AW, Allen NB, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation 2025;151:e41\u2013660. https:\/\/doi.org\/10.1161\/CIR.0000000000001303; PMID:\u00a039866113."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 2020;396:121\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)30748-0; PMID:\u00a032446323.","DOI":"10.1016\/S0140-6736(20)30748-0"},{"key":"ref2","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID:\u00a034447992."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chan DZL, Kerr AJ, Doughty RN. Temporal trends in the burden of heart failure. Intern Med J 2021;51:1212\u20138. https:\/\/doi.org\/10.1111\/imj.15253; PMID:\u00a033650267.","DOI":"10.1111\/imj.15253"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Seferovi\u0107 PM, Vardas P, Jankowska EA, et al. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail 2021;23:906\u201314. https:\/\/doi.org\/10.1002\/ejhf.2143; PMID:\u00a033634931.","DOI":"10.1002\/ejhf.2143"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol 2019;73:935\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.049; PMID:\u00a030819362.","DOI":"10.1016\/j.jacc.2018.11.049"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Escobar C, Palacios B, Varela L, et al. Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. J Clin Med 2022;11:5199. https:\/\/doi.org\/10.3390\/jcm11175199; PMID:\u00a036079133.","DOI":"10.3390\/jcm11175199"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Sicras-Mainar A, Sicras-Navarro A, Palacios B, et al. Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Rev Esp Cardiol (Engl Ed) 2022;75:31\u20138. https:\/\/doi.org\/10.1016\/j.rec.2020.09.033; PMID:\u00a033380382.","DOI":"10.1016\/j.rec.2020.09.033"},{"key":"ref8","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, et al. Management of worsening heart failure with reduced ejection fraction: JACC focus Seminar 3\/3. J Am Coll Cardiol 2023;82:559\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.057; PMID:\u00a037532426."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1915928; PMID:\u00a032222134.","DOI":"10.1056\/NEJMoa1915928"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Iyngkaran P, Toukhsati SR, Thomas MC, et al. A review of the external validity of clinical trials with beta-blockers in heart failure. Clin Med Insights Cardiol 2016;10:163\u201371. https:\/\/doi.org\/10.4137\/CMC.S38444; PMID:\u00a027773994.","DOI":"10.4137\/CMC.S38444"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Galv\u00e1n Ruiz M, Fern\u00e1ndez de Sanmamed Gir\u00f3n M, Del Val Groba Marco M, et al. Clinical profile, associated events and safety of vericiguat in a real-world cohort: the VERITA study. ESC Heart Fail 2024;11:4222\u201330. https:\/\/doi.org\/10.1002\/ehf2.15032; PMID:\u00a039155141.","DOI":"10.1002\/ehf2.15032"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245\u201355. https:\/\/doi.org\/10.1016\/s0735-1097(00)00531-3; PMID:\u00a010758967.","DOI":"10.1016\/S0735-1097(00)00531-3"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Stolk E, Ramos-Go\u00f1i JM, Ludwig K, et al. The development and strengthening of methods for valuing EQ-5D-5L\u2014an overview. In: Devlin N, Roudijk B, Ludwig K, eds. Value sets for EQ-5D-5L: A compendium, comparative review & user guide. Cham, Switzerland: Springer, 2022; 13\u201327. https:\/\/doi.org\/10.1007\/978-3-030-89289-0_2.","DOI":"10.1007\/978-3-030-89289-0_2"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Klimek L, Bergmann KC, Biedermann T, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the Working Group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int 2017;26:16\u201324. https:\/\/doi.org\/10.1007\/s40629-016-0006-7; PMID:\u00a028217433.","DOI":"10.1007\/s40629-016-0006-7"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Esteban-Fern\u00e1ndez A, Recio-Mayoral A, L\u00f3pez-Vilella R, et al. Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial. Front Cardiovasc Med 2025;11:1504427. https:\/\/doi.org\/10.3389\/fcvm.2024.1504427; PMID:\u00a039850382.","DOI":"10.3389\/fcvm.2024.1504427"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Russo Botero S, Ripoll Mart\u00ednez M, F\u00e1cila Rubio L, et al. VERICIDuAT: real-life study of vericiguat in patients with heart failure with reduced ejection fraction. Rev Clin Esp (Barc) 2025;225:204\u201310. https:\/\/doi.org\/10.1016\/j.rceng.2025.02.006; PMID:\u00a039986439.","DOI":"10.1016\/j.rceng.2025.02.006"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Escobar C, Salda\u00f1a J, Merino JL, Peinado R. Vericiguat in patients with heart failure and implantable cardioverter-defibrillator. Drugs Context 2025;14:2024-10-5. https:\/\/doi.org\/10.7573\/dic.2024-10-5; PMID:\u00a040078952.","DOI":"10.7573\/dic.2024-10-5"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Okami S, Ohlmeier C, Takeichi M, et al. Vericiguat use in patients with heart failure in real-world settings during the first year after the drug authorization in Japan. J Clin Med 2024;13:3222. https:\/\/doi.org\/10.3390\/jcm13113222; PMID:\u00a038892932.","DOI":"10.3390\/jcm13113222"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Imamura T, Kinugawa K. Who can receive clinical benefit from mid-term vericiguat add-on therapy among patients with systolic heart failure receiving quadruple medical therapy? Int Heart J 2024;65:684\u201392. https:\/\/doi.org\/10.1536\/ihj.24-091; PMID:\u00a039010220.","DOI":"10.1536\/ihj.24-091"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Suzuki H, Inoue T, Terui Y, et al. Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction. ESC Heart Fail 2024;11:2451\u20134. https:\/\/doi.org\/10.1002\/ehf2.14802; PMID:\u00a038685602.","DOI":"10.1002\/ehf2.14802"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Fujii C, Hiraishi M, Yamashita K, et al. Effect of vericiguat on left ventricular reverse remodeling in patients who have heart failure with reduced ejection fraction \u2013 special focus on patients without quadruple medical therapy. Circ Rep 2024;6:448\u201355. https:\/\/doi.org\/10.1253\/circrep.CR-24-0076; PMID:\u00a039391547.","DOI":"10.1253\/circrep.CR-24-0076"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Nakamura M, Imamura T, Kinugawa K. Initial experience of vericiguat treatment in patients with heart failure and reduced ejection fraction. J Clin Med 2023;12:4396. https:\/\/doi.org\/10.3390\/jcm12134396; PMID:\u00a037445431.","DOI":"10.3390\/jcm12134396"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Tian J, Dong M, Sun X, et al. Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: insights from a 6-month real-world study. Int J Cardiol 2024;417:132524. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132524; PMID:\u00a039244100.","DOI":"10.1016\/j.ijcard.2024.132524"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zhao D, Zhang Y, Yong Y, et al. Vericiguat combined with \u201cnew quadruple\u201d therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study. Front Cardiovasc Med 2024;11:1476976. https:\/\/doi.org\/10.3389\/fcvm.2024.1476976; PMID:\u00a039465136.","DOI":"10.3389\/fcvm.2024.1476976"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wang Q, Wang G, Peng J, et al. Characterizing vericiguat treatment in heart failure: a multicenter real-world study in china. Rev Cardiovasc Med 2024;25:427. https:\/\/doi.org\/10.31083\/j.rcm2512427; PMID:\u00a039742246.","DOI":"10.31083\/j.rcm2512427"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zhan Y, Li L, Zhou J, et al. Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study. BMC Cardiovasc Disord 2025;25:83. https:\/\/doi.org\/10.1186\/s12872-025-04477-2; PMID:\u00a039910422.","DOI":"10.1186\/s12872-025-04477-2"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kerwagen F, Ohlmeier C, Evers T, et al. Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany. Eur J Clin Pharmacol 2024;80:931\u201340. https:\/\/doi.org\/10.1007\/s00228-024-03654-0; PMID:\u00a038472389.","DOI":"10.1007\/s00228-024-03654-0"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Patel P, Mishra A, Gawande SM, et al. Elevating expectations: vericiguat in heart failure with reduced ejection fraction. J Pharm Bioallied Sci 2024;16(Suppl 4):S4010\u20132. https:\/\/doi.org\/10.4103\/jpbs.jpbs_1392_24, Epub. PMID:\u00a039926952.","DOI":"10.4103\/jpbs.jpbs_1392_24"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Butler J, Stebbins A, Melenovsk\u00fd V, et al. Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial. Circ Heart Fail 2022;15:e009337. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009337; PMID:\u00a035656822.","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Bernal BC, Oca\u00f1a FC, P\u00e9rez PJG, Jurado FJC. Experience of the use of vericiguat in patients with heart failure in our setting. Rev Esp Cardiol 2024;77(Suppl 1):1138. https:\/\/doi.org\/10.1016\/S0300-8932(25)01141-8.","DOI":"10.1016\/S0300-8932(25)01141-8"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Rubio BJ, Flores JP, Mateo VM, et al. Registry of patients with heart failure and reduced LVEF under treatment with vericiguat in Castilla la Mancha. Rev Esp Cardiol 2024;77(Suppl 1):1137. https:\/\/doi.org\/10.1016\/S0300-8932(25)01140-6.","DOI":"10.1016\/S0300-8932(25)01140-6"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hashimoto T, Yoshitake T, Suenaga T, et al. Effectiveness of vericiguat on right ventricle to pulmonary artery uncoupling associated with heart failure with reduced ejection fraction. Int J Cardiol 2024;415:132441. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132441; PMID:\u00a039134125.","DOI":"10.1016\/j.ijcard.2024.132441"},{"key":"ref33","unstructured":"Ezekowitz JA, O\u2019Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: Vericiguat Heart Failure with Reduced Ejection Fraction study. JACC Heart Fail 2020;8:931\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2020.08.008; PMID:\u00a033039447."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Senni M, Lopez-Sendon J, Cohen-Solal A, et al. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Fail 2022;9:3791\u2013803. https:\/\/doi.org\/10.1002\/ehf2.14050; PMID:\u00a035880474.","DOI":"10.1002\/ehf2.14050"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Senni M, Alemayehu WG, Sim D, et al. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: insights from the VICTORIA trial. Eur J Heart Fail 2022;24:1614\u201322. https:\/\/doi.org\/10.1002\/ejhf.2608; PMID:\u00a035791083.","DOI":"10.1002\/ejhf.2608"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Aimo A, Pateras K, Stamatelopoulos K, et al. Relative efficacy of Sacubitril-Valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther 2021;35:1067\u201376. https:\/\/doi.org\/10.1007\/s10557-020-07099-2; PMID:\u00a033074526.","DOI":"10.1007\/s10557-020-07099-2"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Chen JL, Gao L, Zhang DY. Treatment strategy for heart failure patients with guideline-directed medical therapy intolerance: a real-world prospective study. Eur Heart J 2024;45(Suppl 1):ehae666.1050. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.1050.","DOI":"10.1093\/eurheartj\/ehae666.1050"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.45","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:46:30Z","timestamp":1776444390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":38,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.45","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"e08"}}